These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 23296045

  • 21. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH, Chuang CC, Wu WC.
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [Abstract] [Full Text] [Related]

  • 22. The relationship of retinal VEGF and retinal IGF-1 mRNA with neovascularization in an acidosis-induced model of retinopathy of prematurity.
    Leske DA, Wu J, Mookadam M, Chen Y, Fautsch MP, Holmes JM, Lanier WL.
    Curr Eye Res; 2006 Feb; 31(2):163-9. PubMed ID: 16500767
    [Abstract] [Full Text] [Related]

  • 23. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study.
    Zhao T, Lu Q, Tao Y, Liang XY, Wang K, Jiang YR.
    Mol Vis; 2011 Apr 27; 17():1044-55. PubMed ID: 21552499
    [Abstract] [Full Text] [Related]

  • 24. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
    Mititelu M, Chaudhary KM, Lieberman RM.
    J Pediatr Ophthalmol Strabismus; 2012 Apr 27; 49(6):332-40. PubMed ID: 22938516
    [Abstract] [Full Text] [Related]

  • 25. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R, Snir M, Ron Y, Friling R, Sirota L, Weinberger D.
    Retina; 2011 Apr 27; 31(7):1239-47. PubMed ID: 21555969
    [Abstract] [Full Text] [Related]

  • 26. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M.
    JAMA Ophthalmol; 2013 Aug 27; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract] [Full Text] [Related]

  • 27. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y, Zhang Y, Zhao T, Jiang YR.
    Am J Ophthalmol; 2012 Feb 27; 153(2):307-313.e2. PubMed ID: 21982107
    [Abstract] [Full Text] [Related]

  • 28. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
    Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA.
    J AAPOS; 2014 Apr 27; 18(2):120-3. PubMed ID: 24698606
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
    Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC.
    Acta Ophthalmol; 2014 Sep 27; 92(6):577-81. PubMed ID: 24020921
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
    Suzuki Y, Suzuki K, Yokoi Y, Miyagawa Y, Metoki T, Nakazawa M.
    Retina; 2014 Jan 27; 34(1):165-71. PubMed ID: 23851630
    [Abstract] [Full Text] [Related]

  • 33. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T.
    Ophthalmology; 2009 May 27; 116(5):921-6. PubMed ID: 19410951
    [Abstract] [Full Text] [Related]

  • 34. A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients.
    Lim JI, Spee C, Hinton DR.
    Retina; 2010 Oct 27; 30(9):1472-8. PubMed ID: 20811317
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.
    Han XX, Guo CM, Li Y, Hui YN.
    Mol Vis; 2012 Oct 27; 18():1-9. PubMed ID: 22232563
    [Abstract] [Full Text] [Related]

  • 37. Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy.
    Fadakar K, Rahmani S, Tedeschi T, Lavine JA, Fawzi AA.
    Invest Ophthalmol Vis Sci; 2024 Apr 01; 65(4):37. PubMed ID: 38652648
    [Abstract] [Full Text] [Related]

  • 38. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
    Suk KK, Berrocal AM, Murray TG, Rich R, Major JC, Hess D, Johnson RA.
    J Pediatr Ophthalmol Strabismus; 2010 Dec 22; 47 Online():e1-4. PubMed ID: 21175113
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A, Dorta P.
    Retina; 2010 Apr 22; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.